申请人:MERRELL DOW PHARMACEUTICALS INC.
公开号:EP0451422A1
公开(公告)日:1991-10-16
This invention relates to novel monofluoromethyl- and difluoromethyltyrosine compounds which are active as tyrosine hydroxylase inhibitors and are therefore useful in the treatment of conditions caused by high levels of catecholamines such as hypertension, schizophrenia, and pheochromocytoma.
这项发明涉及新颖的单氟甲基和二氟甲基酪氨酸化合物,这些化合物作为酪氨酸羟化酶抑制剂具有活性,因此在治疗由高儿茶酚胺水平引起的疾病,如高血压、精神分裂症和嗜铬细胞瘤方面具有用途。